Company Overview

PAVmed Inc. is a medical technology company focused on the development, commercialization, and monetization of innovative medical devices and diagnostic technologies. The company operates primarily within the medical devices, diagnostics, and healthcare technology industries, targeting unmet clinical needs with products designed to improve patient outcomes and reduce healthcare costs. Its business model combines direct commercialization, strategic partnerships, and the incubation of subsidiary companies.

The company’s primary revenue drivers are derived from medical device sales, diagnostic testing services through subsidiaries, and licensing or strategic transactions involving its technologies. PAVmed serves hospitals, physician practices, ambulatory surgical centers, and diagnostic laboratories, with a strategic emphasis on minimally invasive solutions and preventative diagnostics. Founded in 2014, PAVmed has evolved from a single-device innovator into a diversified medical technology platform with multiple clinical-stage and commercial assets, including publicly traded subsidiaries.

Business Operations

PAVmed operates through several core business lines encompassing vascular access devices, surgical implants, and diagnostic testing technologies. Key operating businesses include PortIO, a minimally invasive intraosseous vascular access system; CarpX, a balloon-based device for the treatment of carpal tunnel syndrome; and its majority-owned subsidiary Lucid Diagnostics, which focuses on early cancer detection. Revenue is generated through product sales, diagnostic testing services, and milestone-based or strategic transactions.

Operations span both domestic and international markets, with commercialization efforts primarily concentrated in the United States and select international regions via distribution partners. PAVmed controls proprietary device designs, intellectual property portfolios, and clinical data supporting regulatory approvals. Its most significant subsidiary, Lucid Diagnostics, operates certified laboratories and markets diagnostic tests to gastroenterologists and primary care providers. Information regarding certain historical subsidiaries and asset dispositions is data inconclusive based on available public sources due to restructuring activity.

Strategic Position & Investments

PAVmed’s strategic direction centers on advancing late-stage clinical assets, supporting the growth of Lucid Diagnostics, and unlocking shareholder value through subsidiary monetization, spin-offs, or strategic partnerships. A notable strategic investment is its controlling ownership stake in Lucid Diagnostics, which is publicly traded and represents PAVmed’s largest operating and investment asset.

The company has historically pursued acquisitions and internal development to expand its technology portfolio, particularly in early disease detection and minimally invasive therapeutic devices. Emerging areas of focus include molecular diagnostics and office-based procedural technologies. Where disclosures regarding future acquisitions or capital allocation are limited or evolving, data inconclusive based on available public sources.

Geographic Footprint

PAVmed is headquartered in the United States and maintains its principal operations there, including executive management, research and development oversight, and commercialization activities. The company’s core market presence is concentrated in North America, particularly the U.S. healthcare system.

International exposure is achieved primarily through distribution agreements and licensing arrangements rather than direct foreign subsidiaries. Through its subsidiaries and partners, PAVmed has a limited but growing footprint in Europe and other select regions. The scale and financial contribution of non-U.S. operations are data inconclusive based on available public sources.

Leadership & Governance

PAVmed was founded by Lishan Aklog, whose leadership philosophy emphasizes physician-led innovation, capital efficiency, and the creation of standalone businesses from internally developed technologies. The company is governed by a board of directors with experience in medicine, finance, and healthcare entrepreneurship, and management has articulated a strategic vision centered on long-term value creation rather than near-term scale.

Key members of leadership include:

• Lishan Aklog – Chairman and Chief Executive Officer
• Adam Levy – President
• Christopher Kerns – Chief Operating Officer
• Andrew Mishra – Chief Financial Officer (Data inconclusive based on available public sources regarding current tenure)

Leadership roles and responsibilities are periodically updated through regulatory filings, and any discrepancies in executive titles or tenure reflect data inconclusive based on available public sources.